KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Short-term Investments (2020 - 2025)

Historic Short-term Investments for Royalty Pharma (RPRX) over the last 6 years, with Q3 2025 value amounting to $16.1 million.

  • Royalty Pharma's Short-term Investments fell 6680.41% to $16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.1 million, marking a year-over-year decrease of 6680.41%. This contributed to the annual value of $58.2 million for FY2024, which is 21803.28% up from last year.
  • As of Q3 2025, Royalty Pharma's Short-term Investments stood at $16.1 million, which was down 6680.41% from $13.2 million recorded in Q2 2025.
  • In the past 5 years, Royalty Pharma's Short-term Investments ranged from a high of $409.3 million in Q3 2022 and a low of $1.3 million during Q4 2022
  • Over the past 5 years, Royalty Pharma's median Short-term Investments value was $38.5 million (recorded in 2024), while the average stood at $71.4 million.
  • Data for Royalty Pharma's Short-term Investments shows a peak YoY increase of 130769.23% (in 2023) and a maximum YoY decrease of 9870.53% (in 2023) over the last 5 years.
  • Royalty Pharma's Short-term Investments (Quarter) stood at $66.0 million in 2021, then crashed by 98.03% to $1.3 million in 2022, then surged by 1307.69% to $18.3 million in 2023, then soared by 218.03% to $58.2 million in 2024, then plummeted by 72.34% to $16.1 million in 2025.
  • Its last three reported values are $16.1 million in Q3 2025, $13.2 million for Q2 2025, and $12.1 million during Q1 2025.